Physician profile
Tabitha J Wolfson
NPI 1346001161
$1,547.68
in general payments reported to CMS, 2019-2025
22 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $507 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $269.96 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $167.55 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $142.36 | 2024-2025 | Airsupra, Farxiga |
| Teva Pharmaceuticals USA, INC. | $129.14 | 2025 | Ajovy |
| Lilly USA, LLC | $111.08 | 2024-2025 | Zepbound, Mounjaro, Kisunla |
| Abbvie INC. | $94.59 | 2024-2025 | |
| Axsome Therapeutics, INC. | $74.30 | 2024-2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $72.09 | 2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $62.67 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lundbeck LLC | $62.47 | 2024-2025 | Rexulti |
| Dexcom, INC. | $52.74 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $49.73 | 2024-2025 | Veozah |
| Vanda Pharmaceuticals INC. | $37.88 | 2025 | Fanapt |
| Pfizer INC. | $36.73 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.85 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $31.29 | 2025 | Trelegy Ellipta, Arexvy |
| Corium, LLC | $26.94 | 2025 | Azstarys |
| Tonix Medicines, INC. | $22.04 | 2025 | Tonmya |
| E.R. Squibb & Sons, L.L.C. | $20.15 | 2025 | Cobenfy |
| Cranial Technologies, INC | $19.45 | 2025 | Doc Band |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.12 | 2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $13.55 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Wolfson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.